- Home
- LPA vs BCAB Comparison
LPA vs BCAB Comparison
Compare LPA & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPA | BCAB |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPA | BCAB |
|---|---|---|
| Price | $2.60 | $0.54 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 29.3K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $47,536,343.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.44 | ★ N/A |
| Revenue Growth | ★ 7.28 | N/A |
| 52 Week Low | $2.55 | $0.24 |
| 52 Week High | $11.16 | $1.43 |
Technical Indicators
Market Signals| Indicator | LPA | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 35.75 |
| Support Level | $2.65 | $0.63 |
| Resistance Level | $2.94 | $0.82 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 2.38 | 1.07 |
Price Performance
Historical ComparisonAbout LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.